Christopher Yasiejko

Philadelphia

Patents/®️/©️, IP@BLaw. Past: @business, @nytimes, @delawareonline. Bylines: @PhillyInquirer, @PhillyDailyNews, @CJR, +. Views=mine. RT≠endorsement. Tips? DM.

Featured in: Favicon

bloomberg.com Favicon

msn.com

indiatimes.com Favicon

latimes.com Favicon

sfgate.com Favicon

smh.com.au Favicon

yahoo.com (+2) Favicon

aljazeera.com Favicon

chicagotribune.com Favicon

fortune.com + 105 more

Articles

Pfizer Sues Alkem to Block Copies of Xeljanz XR Arthritis Drug

6 days ago | news.bloomberglaw.com | Christopher Yasiejko

The Pfizer Inc. logo sits on a sign near their medical manufacturing facility at Discovery Park in Sandwich, U.K., on Friday, Aug. 21, 2020. Photographer: Chris Ratcliffe/Bloomberg May 8, 2025, 8:54 PM UTC Christopher Yasiejko Senior correspondentCOURT: D. Del. TRACK DOCKET: No. 25-cv-565 (Bloomberg Law subscription)Alkem Laboratories Ltd.'s proposed copies of two extended-release Xeljanz dosages infringe a patent for Pfizer Inc.'s once-blockbuster arthritis drug, a federal lawsuit said.
Pfizer Sues Alkem to Block Copies of Xeljanz XR Arthritis Drug

6 days ago | news.bloombergtax.com | Christopher Yasiejko

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says

1 week ago | news.bloomberglaw.com | Christopher Yasiejko

Signage is displayed at the Sun Pharmaceutical Industries Ltd. headquarters in Mumbai, India, on Thursday, May 2, 2019. Photographer: Kanishka Sonthalia/Bloomberg May 7, 2025, 4:10 PM UTC Christopher Yasiejko Senior correspondentFederal Circuit says patent can’t justify blocking launchIncyte’s rival drug won’t launch before patent expiresSun Pharmaceutical Industries Ltd. can launch its new hair-loss drug Leqselvi after the Federal Circuit reversed a district judge’s order granting Incyte Corp.
Federal Circuit Keeps FDA Hold in MSN-Novartis Drug-Patent Fight

1 week ago | news.bloomberglaw.com | Christopher Yasiejko

A Delaware district court must maintain its pause of an order that the FDA delay final approval of MSN Laboratories Pvt. Ltd.’s copy of Entresto while an appeals court considers MSN’s request to block it, the Federal Circuit ruled. The generic-drug maker is appealing rulings that block the early launch of its copy of the blockbuster heart-disease drug and preserve Novartis’ market exclusivity until a patent’s pediatric exclusivity expires in July.
Federal Circuit Keeps FDA Hold in MSN-Novartis Drug-Patent Fight

1 week ago | news.bloombergtax.com | Christopher Yasiejko

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.
UTC Bid to Delay Launch of Liquidia’s Yutrepia Shot Down (3)

1 week ago | news.bloombergtax.com | Christopher Yasiejko |Nyah Phengsitthy

A federal judge dismissed United Therapeutics Corp.'s cross-claims against Liquidia Corp. and the US Food and Drug Administration, allowing Liquidia’s lung-disease drug Yutrepia to move forward for a launch as early as this month. Judge Timothy J. Kelly’s order, issued Friday in the US District Court for the District of Columbia, means Liquidia’s Yutrepia can receive final approval and launch when UTC’s exclusivity for the dry-powder-inhalation version of its blockbuster Tyvaso expires May 23.
UTC Bid to Delay Liquidia’s Yutrepia Launch Shot Down by Judge

1 week ago | news.bloomberglaw.com | Christopher Yasiejko |Nyah Phengsitthy

A federal judge dismissed United Therapeutics Corp.'s cross-claims against Liquidia Corp. and the US Food and Drug Administration, allowing Liquidia’s lung-disease drug Yutrepia to move forward for a launch as early as this month. Judge Timothy J. Kelly’s order, issued Friday in the US District Court for the District of Columbia, means Liquidia’s Yutrepia can receive final approval and launch when UTC’ exclusivity for the dry-powder-inhalation version of its blockbuster Tyvaso expires May 23.
MSN Asks Federal Circuit to Revive Entresto Patent Delisting Bid

1 week ago | news.bloombergtax.com | Christopher Yasiejko

MSN Laboratories Pvt. Ltd. is appealing rulings that block the early launch of its copy of Entresto and preserve Novartis AG’s market exclusivity for the blockbuster heart-disease drug until a patent’s pediatric exclusivity expires in July. MSN is asking the Federal Circuit to overturn Judge Richard G.
MSN Asks Federal Circuit to Revive Entresto Patent Delisting Bid

1 week ago | news.bloomberglaw.com | Christopher Yasiejko

Pharma & Life SciencesEmailMay 1, 2025, 5:03 PM UTCMSN Laboratories Pvt. Ltd. is appealing rulings that block the early launch of its copy of Entresto and preserve Novartis AG’s market exclusivity for the blockbuster heart-disease drug until a patent’s pediatric exclusivity expires in July. MSN is asking the Federal Circuit to overturn Judge Richard G.
Pfizer, BioNTech Fail to Void Alnylam’s Covid-Shot Patent Claims

2 weeks ago | news.bloombergtax.com | Christopher Yasiejko

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.